Company intelligence / Profile preview
Evommune
Los Altos, California, United Statesevommune.com ↗
- Ownership
- Public · EVMN
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase 2 trial of EVO756, an oral MRGPRX2 antagonist, for chronic inducible urticaria[3]
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small molecules (EVO756 is mentioned as an oral antagonist)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Maruho (strategic collaboration to develop and commercialize MRGPRX2 antagonist EVO756 in Japan)[3]
04
Financials
- Market cap
- $231.2M
- Total revenue
- $13M
- Enterprise value
- $38.5M
Beyond the preview
Go deeper on Evommune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evommune.